DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors (NCT05785754)
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a multicenter, open-label, Phase 1 study to assess the effects of DCSZ11 as a monotherapy and in combination in patients with advanced or metastatic solid tumors. The study consists of an Escalation Phase (Phase 1a) and a Dose Expansion/Optimization Phase (Phase 1b).
Who can join: Review the eligibility criteria below.
Location: University of Alabama — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (35 Sites)
Showing the first 25 of 35 sites.
- University of Alabama — Birmingham, Alabama
- Mayo Clinic — Phoenix, Arizona
- HonorHealth — Scottsdale, Arizona
- University of Colorado — Aurora, Colorado
- Sarah Cannon Research Institute Denver Healthone — Denver, Colorado
- Yale Cancer Center — New Haven, Connecticut
- Mayo Clinic — Jacksonville, Florida
- University of Miami — Miami, Florida
- John Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
- Dana Farber Cancer Institute — Boston, Massachusetts
- Mayo Clinic — Rochester, Minnesota
- MonteFiore — The Bronx, New York
- Ohio State University — Columbus, Ohio
- SCRI Oncology Partners — Nashville, Tennessee
- Scientia Clinical Research — Randwick, New South Wales
- St Vincent's Hospital — Sydney, New South Wales
- University of Sunshine Coast — Buderim, Queensland
- Southern Oncology Clinical Research Unit (SOCRU) — Bedford Park, South Australia
- The Queen Elizabeth Hospital (TQEH) — Woodville South, South Australia
- Monash Health — Clayton, Victoria
- Cabrini Hospital — Malvern, Victoria
- Linear Clinical Research Limited — Nedlands, Western Australia
- Townsville Hospital — Douglas,
- Liverpool Hospital — Liverpool,
- Mater Misericordiae Health Services Brisbane Ltd — South Brisbane,
📞 Contact the Study Coordinator
Phone: (781) 373-9136
Email: alejandrogomez@dynamicure.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced or Metastatic Solid Tumors
- A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) — Sioux Falls, South Dakota
- A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors — Denver, Colorado
- A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations — San Francisco, California
- Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors — Boston, Massachusetts
- A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors — Birmingham, Alabama
- A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors — Los Angeles, California
Explore by condition: All Advanced or Metastatic Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.